[Click eStock] "Nextbiomedical Enters Lower Gastrointestinal Market"

NH Investment & Securities forecasted on the 29th that Nextbiomedical will rapidly grow next year by entering the lower gastrointestinal market.

Sehoon Son, a researcher at NH Investment & Securities, explained, "The U.S. Food and Drug Administration (FDA) has approved the expansion of indications for NexPowderTM in the lower gastrointestinal tract," adding, "Existing endoscopic hemostasis techniques are more likely to cause perforation in the lower gastrointestinal tract, where the membrane is thinner than in the upper part."

He continued, "Next year, the company has laid the foundation to fully enter a market with high demand," and added, "NexPowder possesses outstanding technology to the extent that it has an exclusive distribution and sales contract with Medtronic, the world's number one medical device company."

He emphasized, "Medtronic is conducting post-market clinical trials in the United States, Canada, and Europe at its own expense."

Researcher Son analyzed, "The anticipated next product is the biodegradable pain embolic agent NexSphereTM-F," and said, "It has received FDA Investigational Device Exemption (IDE) approval and will begin clinical trials next year." He further predicted, "Thanks to continuous research and development leading to product launches such as drug-loaded endoscopic hemostatic agents and sustained-release drug microparticles, steady growth is expected."

This content was produced with the assistance of AI translation services.